Foresite Capital Fund II, L.P.
CIK 0001594914 Name as filed on the most recent filing
Filed as Foresite Capital Fund II, L.P. (16)
37 transaction lines · from 16 filings · filed 2015-08-11 to 2020-05-14 The span is the filing dates this catalog holds, not the entity's full filing history. Absence here is not evidence of absence at the SEC.
A line appears here when the filing that carries it names this CIK as a reporting owner, not only when the parser picked this CIK as the line's primary owner. That is why a joint filing appears on both owners' pages rather than vanishing from the second one. The catalog never merges two CIKs into one person and never splits one CIK into two: identity here is the SEC's own identifier and nothing else.
Issuers this insider has filed against
Ordered by last-seen filing date, newest first. Roles are as filed on the Form 4 and are not normalised.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
- ISSUER 10x Genomics, Inc. 3 filings
- ISSUER Aerie Pharmaceuticals Inc 10 filings
- ISSUER Aimmune Therapeutics, Inc. 3 filings
No issuer is recorded
The catalog holds no filing linking this CIK to an issuer.
Transactions
Every stored Form 4 line naming this reporting owner, newest transaction date first. Each row links to the filing it came from.
0 transactions · Newest transaction date first, id breaking the tie.
This container could not be filled from the store. It is showing nothing because a read failed, not because no insider filed: those are different facts and this catalog will not let one stand in for the other. The last ingest the store recorded was 2026-08-20 05:22 UTC.
| Direction | Date | Issuer | Code | Shares | Price | Value USD | Filing |
|---|---|---|---|---|---|---|---|
| 2020-05-13 |
10x Genomics, Inc. TXG |
S, Open-market sale | 800,000 disposed | 80.13 | 64,104,000.00 | Form 4, filing 0000899243-20-013113 | |
| 2020-05-13 |
10x Genomics, Inc. TXG |
S, Open-market sale | 650,000 disposed | 80.13 | 52,084,500.00 | Form 4, filing 0000899243-20-013113 | |
| 2020-03-17 |
10x Genomics, Inc. TXG |
S, Open-market sale | 500,000 disposed | 59.00 | 29,500,000.00 | Form 4, filing 0000899243-20-009021 | |
| 2020-03-17 |
10x Genomics, Inc. TXG |
S, Open-market sale | 250,000 disposed | 59.00 | 14,750,000.00 | Form 4, filing 0000899243-20-009021 | |
| 2020-02-27 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 425,457 disposed | 17.07 | 7,262,550.99 | Form 4, filing 0001209191-20-014562 | |
| 2020-02-27 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 302,776 disposed | 17.07 | 5,168,386.32 | Form 4, filing 0001209191-20-014562 | |
| 2020-02-27 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 271,767 disposed | 17.07 | 4,639,062.69 | Form 4, filing 0001209191-20-014562 | |
| 2019-09-12 |
10x Genomics, Inc. TXG |
P, Open-market purchase | 187,500 acquired | 39.00 | 7,312,500.00 | Form 4, filing 0001209191-19-049680 | |
| 2019-09-05 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 15,700 acquired | 18.42 | 289,194.00 | Form 4, filing 0001209191-19-048830 | |
| 2019-09-04 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 90,900 acquired | 18.48 | 1,679,832.00 | Form 4, filing 0001209191-19-048830 | |
| 2019-09-04 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 9,300 acquired | 18.48 | 171,864.00 | Form 4, filing 0001209191-19-048830 | |
| 2019-09-03 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 34,900 acquired | 20.54 | 716,846.00 | Form 4, filing 0001209191-19-048394 | |
| 2019-09-03 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 15,100 acquired | 21.45 | 323,895.00 | Form 4, filing 0001209191-19-048394 | |
| 2019-08-30 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 25,000 acquired | 21.36 | 534,000.00 | Form 4, filing 0001209191-19-048394 | |
| 2019-08-23 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 38,300 acquired | 23.42 | 896,986.00 | Form 4, filing 0001209191-19-047387 | |
| 2019-08-22 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 6,700 acquired | 23.68 | 158,656.00 | Form 4, filing 0001209191-19-047387 | |
| 2019-08-21 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 1,153 acquired | 23.25 | 26,807.25 | Form 4, filing 0001209191-19-047387 | |
| 2019-08-20 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 50,000 acquired | 23.21 | 1,160,500.00 | Form 4, filing 0001209191-19-046913 | |
| 2019-08-19 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 3,847 acquired | 23.34 | 89,788.98 | Form 4, filing 0001209191-19-046913 | |
| 2019-08-16 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 100,000 acquired | 24.23 | 2,423,000.00 | Form 4, filing 0001209191-19-046913 | |
| 2019-08-14 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 100,000 acquired | 23.73 | 2,373,000.00 | Form 4, filing 0001209191-19-046012 | |
| 2019-08-13 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 178,903 acquired | 25.52 | 4,565,604.56 | Form 4, filing 0001209191-19-046012 | |
| 2019-08-13 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 71,097 acquired | 24.92 | 1,771,737.24 | Form 4, filing 0001209191-19-046012 | |
| 2019-08-12 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 189,555 acquired | 24.43 | 4,630,828.65 | Form 4, filing 0001209191-19-046012 | |
| 2017-05-26 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 10,182 disposed | 55.95 | 569,682.90 | Form 4, filing 0001209191-17-036603 | |
| 2017-05-26 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 9,818 disposed | 55.95 | 549,317.10 | Form 4, filing 0001209191-17-036603 | |
| 2016-10-06 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 24,813 disposed | 40.34 | 1,000,953.94 | Form 4, filing 0001209191-16-145532 | |
| 2016-10-06 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 25,187 disposed | 40.34 | 1,016,041.06 | Form 4, filing 0001209191-16-145532 | |
| 2016-10-06 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 25,187 disposed | 40.34 | 1,016,041.06 | Form 4, filing 0001209191-16-145487 | |
| 2016-10-06 |
Aerie Pharmaceuticals Inc AERI |
S, Open-market sale | 24,813 disposed | 40.34 | 1,000,953.94 | Form 4, filing 0001209191-16-145487 | |
| 2016-07-22 |
Aerie Pharmaceuticals Inc AERI |
P, Open-market purchase | 250,000 acquired | 17.50 | 4,375,000.00 | Form 4, filing 0001209191-16-133904 | |
| 2016-05-31 |
Aimmune Therapeutics, Inc. AIMT |
S, Open-market sale | 120,000 disposed | 15.23 | 1,827,360.00 | Form 4, filing 0001209191-16-125229 | |
| 2016-05-31 |
Aimmune Therapeutics, Inc. AIMT |
S, Open-market sale | 120,000 disposed | 15.23 | 1,827,360.00 | Form 4, filing 0001209191-16-125229 | |
| 2015-08-24 |
Aimmune Therapeutics, Inc. AIMT |
P, Open-market purchase | 25,485 acquired | 19.65 | 500,900.03 | Form 4, filing 0001209191-15-068040 | |
| 2015-08-11 |
Aimmune Therapeutics, Inc. AIMT |
P, Open-market purchase | 312,500 acquired | 16.00 | 5,000,000.00 | Form 4, filing 0000899243-15-002782 | |
| 2015-08-11 |
Aimmune Therapeutics, Inc. AIMT |
P, Open-market purchase | 312,500 acquired | 16.00 | 5,000,000.00 | Form 4, filing 0000899243-15-002782 | |
| 2015-08-11 |
Aimmune Therapeutics, Inc. AIMT |
P, Open-market purchase | 17,035 acquired | 20.50 | 349,198.76 | Form 4, filing 0000899243-15-002782 |
This column is intentionally blank
No transaction line is stored for this reporting owner, though the catalog holds filings naming them. That happens when the filings report only holdings or only positions the store does not carry, and when a parse failed; each filing page states its own parse status.
- S, Open-market sale
- Open-market sale
- P, Open-market purchase
- Open-market purchase
Every value is as reported on the Form 4. A price the filing did not report is marked Not reported and no value is computed from it. Codes outside the open market, drawn in grey behind a dashed rule, are compensation and administrative machinery rather than a decision to trade at the prevailing price.
What this insider's stored lines contain
No transaction line is stored for this entity, so there is nothing to break down by code. The catalog holds its filings; what it does not hold is a single reportable line from them, which is a fact about the parse and about these filings, not about the entity.
How to cite this page
ebomi catalog. Foresite Capital Fund II, L.P., insider transactions. Retrieved 2026-08-20 from https://ebomi.com/insider/0001594914
Balogh, A. Insider trading. Scientific Data 10, 237 (2023) doi:10.1038/s41597-023-02147-6